Abstract:Targeting protein-protein interactions (PPIs) has emerged as a viable approach in modern drug discovery. However, the identification of small molecules enabling us to effectively interrupt their interactions presents significant challenges. In the recent past, significant advances have been made in the development of new biological and chemical strategies to facilitate the discovery process of small-molecule PPI inhibitors. This review aims to highlight the state-of-the-art technologies and the achievements made recently in this field. The "hot spots" of PPIs have been proved to be critical for small molecules to bind. Three strategies including screening, designing, and synthetic approaches have been explored for discovering PPI inhibitors by targeting the "hot spots". Although the classic high throughput screening approach can be used, fragment screening, fragment-based drug design and newly improved virtual screening are demonstrated to be more effective in the discovery of PPI inhibitors. In addition to screening approaches, design strategies including anchor-based and small molecule mimetics of secondary structures involved in PPIs have become powerful tools as well. Finally, constructing new chemically spaced libraries with high diversity and complexity is becoming an important area of interest for PPI inhibitors. The successful cases from the recent five year studies are used to illustrate how these approaches are implemented to uncover and optimize small molecule PPI inhibitors and notably some of them have become promising therapeutics.

Protein-protein interaction: a novel direction for discovering anti-tumor drugs

Small molecules targeting protein‒protein interactions for cancer therapy

State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors

Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions

Novel Anticancer Targets and Drug Discovery in Post Genomic Age

Comprehensive Analysis Of Cancer Drugs Based On Human Protein-Protein Interaction Network Profiles Of These Targets

Targeting Protein-Protein Interaction by Small Molecules

New insights into protein–protein interaction modulators in drug discovery and therapeutic advance

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

Utilization of Macrocyclic Peptides to Target Protein-Protein Interactions in Cancer.

Tachyplesin I and its derivatives: A pharmaco-chemical perspective on their antimicrobial and antitumor potential

Computational Identification of Inhibitors of Protein-Protein Interactions.

Chemical Proteomic Strategies for the Discovery and Development of Anticancer Drugs

Research Progress of Inhibitors of Peptides and Peptidomimetic Acting on P 53-MDM2 I Nte Rf Ace

Advances on Small-Molecule Inhibitors of Interfacing with P53-Mdm2 Protein-Protein Interactions

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research

Rational design of peptide inhibitors targeting HSP90–CDC37 protein–protein interaction

Covalent Binding Design Strategy: A Prospective Method for Discovery of Potent Targeted Anticancer Agents.

Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation

Multi-level bioinformatics resources support drug target discovery of protein-protein interactions